Literature DB >> 16823111

Cell and tissue engineering and clinical applications: an overview.

J F Stoltz1, D Bensoussan, V Decot, A Ciree, P Netter, P Gillet.   

Abstract

Most human tissues do not regenerate spontaneously; this is why cell therapies and tissue engineering are promising alternatives. The principle is simple: cells are collected in a patient and introduced in the damaged tissue or in a tridimentional porous support and harvested in a bioreactor in which the physico-chemical and mechanical parameters are controlled. Once the tissues (or the cells) are mature they may be implanted. In parallel, the development of biotherapies with stem cells is a field of research in turmoil given the hopes for clinical applications that it brings up. Embryonic stem cells are potentially more interesting since they are totipotent, but they can only be obtained at the very early stages of the embryo. The potential of adult stem cells is limited but isolating them induces no ethical problem and it has been known for more than 40 years that bone marrow does possess the regenerating functions of blood cells. Finally, the properties of foetal stem cells (blood cells from the umbilical cord) are forerunners of the haematopoietic system but the ability of these cells to participate to the formation of other tissues is more problematic. Another field for therapeutic research is that of dendritic cells, antigen presenting cells. Their efficiency in cell therapy relies on the initiation of specific immune responses. They represent a promising tool in the development of a protective immune response against antigens which the host is usually unable to generate an efficient response (melanomas, breast against cancer, prostate cancer, ..). Finally, gene therapy, has been nourishing high hopes but few clinical applications can be envisaged in the short term, although potential applications are multiple (haemophilia, myopathies, ..). A large number of clinical areas stand as candidates for clinical applications: leukaemia and cancers, cardiac insufficiency and vascular diseases, cartilage and bone repair, ligaments and tendons, liver diseases, ophthalmology, diabetes, neurological diseases (Parkinson, Huntington disease, ..), .. Various aspects of this new regenerative therapeutic medicine are developed in this work.

Entities:  

Mesh:

Year:  2006        PMID: 16823111

Source DB:  PubMed          Journal:  Biomed Mater Eng        ISSN: 0959-2989            Impact factor:   1.300


  4 in total

1.  Electrical Characterization of 3D Au Microelectrodes for Use in Retinal Prostheses.

Authors:  Sangmin Lee; Jae Hyun Ahn; Jong-Mo Seo; Hum Chung; Dong-Il Dan Cho
Journal:  Sensors (Basel)       Date:  2015-06-17       Impact factor: 3.576

2.  MMP9 integrates multiple immunoregulatory pathways that discriminate high suppressive activity of human mesenchymal stem cells.

Authors:  Carolina Lavini-Ramos; Hernandez Moura Silva; Alessandra Soares-Schanoski; Sandra Maria Monteiro; Ludmila Rodrigues Pinto Ferreira; Ana Paula Pacanaro; Samirah Gomes; Janaína Batista; Kellen Faé; Jorge Kalil; Verônica Coelho
Journal:  Sci Rep       Date:  2017-04-13       Impact factor: 4.379

3.  Are the Immune Properties of Mesenchymal Stem Cells from Wharton's Jelly Maintained during Chondrogenic Differentiation?

Authors:  Charlotte Voisin; Ghislaine Cauchois; Loïc Reppel; Caroline Laroye; Laetitia Louarn; Chantal Schenowitz; Paulin Sonon; Isabelle Poras; Valentine Wang; Edgardo D Carosella; Nadia Benkirane-Jessel; Philippe Moreau; Nathalie Rouas-Freiss; Danièle Bensoussan; Céline Huselstein
Journal:  J Clin Med       Date:  2020-02-04       Impact factor: 4.241

4.  A bioreactor model of mouse tumor progression.

Authors:  George A Thouas; John Sheridan; Kerry Hourigan
Journal:  J Biomed Biotechnol       Date:  2007
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.